Sanofi soars on the Paris Stock Exchange after reporting better-than-expected results

Sanofi’s share price soars following a third quarter of very positive results. The French pharmaceutical giant has recorded a 15.2 per cent increase in net turnover since the start of the year and an operating profit of 4.35 billion, whilst earnings per share reached 3.55 euros, allowing for an upward revision of the guidance for 2026: revenue growth is now expected to be “in the low single-digit range”.

This increase is “driven mainly by our new medicines and by Dupixent”, said Chief Executive Belén Garijo. Duxipent, a medicine for the treatment of atopic dermatitis, has in fact quickly become the French pharmaceutical company’s flagship product, exceeding 5 billion in quarterly sales for the second time.

The market reaction has been positive: Sanofi shares are up by almost 5 per cent, rising to around 80 euros compared with Thursday’s closing price of 76.15 euros.

The results come at a strategic time for the French group, which is seeking products robust enough to offset the loss of the Dupixent patent, due to expire by the end of this decade. Following the announcement on 1 October regarding the strengthening of its collaboration with the US-based company Regeneron, the two firms have agreed to develop four new antibodies designed to target type 2 inflammation – the same mechanism involved in Dupixent’s action. Under the agreement, Regeneron will lead the research whilst Sanofi will be responsible for global commercialisation, but both will share equally in the future revenues from the potential programmes currently in development.